Chronic Nodular Prurigo: An Update on the Pathogenesis and Treatment

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Oct 27

PMID 36293248

Authors

Lai-San Wong

Yu-Ta Yen

Affiliations

Soon will be listed here.

Abstract

Chronic nodular prurigo (CNPG) is a recalcitrant chronic itchy disorder that affects the quality of life. It can be triggered by multiple etiologies, such as atopic dermatitis, diabetes, and chronic renal diseases. The mechanisms of CNPG are complicated and involved the interaction of the cutaneous, immune, and nervous systems. Diverse immune cells, including eosinophils, neutrophils, T cells, macrophages, and mast cells infiltrated the lesional skin of CNPG, which initiated the inflammatory cytokines and pruritogens release. In addition, the interaction between the immune cells and activated peripheral sensory nerve fibers by neurotransmitters caused neuroinflammation in the skin and intractable itch. This itch-scratch vicious cycle of CNPG results in disease exacerbation. CNPG is difficult to treat with traditional therapies. Recently, great advances have been made in the pathophysiology of both inflammation and pruritus transmission in CNPG. In this review, we summarize the updated mechanisms and novel therapies for CNPG.

Citing Articles

Abrocitinib as a novel therapeutic approach for refractory prurigo nodularis: real-world evidence.

Demirbas A, Diremsizoglu E, Cinar G, Vural C Arch Dermatol Res. 2025; 317(1):543.

PMID: 40064674 DOI: 10.1007/s00403-025-04071-8.

Effective Treatment of Prurigo Nodularis With Oral Tofacitinib: A Case Report.

Mozafari N Clin Case Rep. 2025; 13(3):e70287.

PMID: 40051903 PMC: 11882762. DOI: 10.1002/ccr3.70287.

The Significant Role of Atopic Skin Diathesis in Prurigo Nodularis.

Erdem Y, Ntousounous O, Ozkaya E Sisli Etfal Hastan Tıp Bul. 2025; 58(4):477-482.

PMID: 39816422 PMC: 11729828. DOI: 10.14744/SEMB.2024.46144.

Paradoxical psoriasis after dupilumab treatment of prurigo nodularis treated with adalimumab.

Sorensen J, Johansen C, Egeberg A, Thyssen J, Thomsen S JAAD Case Rep. 2024; 52:146-149.

PMID: 39399233 PMC: 11467471. DOI: 10.1016/j.jdcr.2024.06.044.

Treatment With Upadacitinib in Refractory Prurigo Nodularis: A Prospective Cohort Study.

Lee J, Kim Y, Shin K, Kim H, Ko H, Kim M Allergy Asthma Immunol Res. 2024; 16(5):546-554.

PMID: 39363772 PMC: 11450437. DOI: 10.4168/aair.2024.16.5.546.

References

Hashimoto T, Nattkemper L, Kim H, Kursewicz C, Fowler E, Shah S . Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. 2021; 30(6):804-810. DOI: 10.1111/exd.14279. View

Lin S, Steinhoff M, Ikoma A, Chang Y, Cheng Y, Chandra Kopparaju R . Involvement of TRPV1 and TDAG8 in Pruriception Associated with Noxious Acidosis. J Invest Dermatol. 2016; 137(1):170-178. DOI: 10.1016/j.jid.2016.07.037. View

Kim M, Jin S, Jang S, Choi J, Chung D, Lee D . IL-17A-Producing Innate Lymphoid Cells Promote Skin Inflammation by Inducing IL-33-Driven Type 2 Immune Responses. J Invest Dermatol. 2019; 140(4):827-837.e9. DOI: 10.1016/j.jid.2019.08.447. View

Furue M, Furue K, Tsuji G, Nakahara T . Interleukin-17A and Keratinocytes in Psoriasis. Int J Mol Sci. 2020; 21(4). PMC: 7072868. DOI: 10.3390/ijms21041275. View

Matsumura S, Terao M, Murota H, Katayama I . Th2 cytokines enhance TrkA expression, upregulate proliferation, and downregulate differentiation of keratinocytes. J Dermatol Sci. 2015; 78(3):215-23. DOI: 10.1016/j.jdermsci.2015.02.021. View

Davenport A, Hyndman K, Dhaun N, Southan C, Kohan D, Pollock J . Endothelin. Pharmacol Rev. 2016; 68(2):357-418. PMC: 4815360. DOI: 10.1124/pr.115.011833. View

Hashimoto T, Namiki T, Iikawa M, Ugajin T, Miura K, Yokozeki H . Prurigo Nodularis in a Patient with Anaplastic Large Cell Lymphoma: A Potential Role for M2-Macrophages in Its Pathogenesis. Ann Dermatol. 2022; 34(2):149-151. PMC: 8989897. DOI: 10.5021/ad.2022.34.2.149. View

Onishi R, Gaffen S . Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology. 2010; 129(3):311-21. PMC: 2826676. DOI: 10.1111/j.1365-2567.2009.03240.x. View

Cevikbas F, Wang X, Akiyama T, Kempkes C, Savinko T, Antal A . A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2013; 133(2):448-60. PMC: 3960328. DOI: 10.1016/j.jaci.2013.10.048. View

10.

Chen Z . A neuropeptide code for itch. Nat Rev Neurosci. 2021; 22(12):758-776. PMC: 9437842. DOI: 10.1038/s41583-021-00526-9. View

11.

Lonndahl L, Lundqvist M, Bradley M, Johansson E . Dupilumab Significantly Reduces Symptoms of Prurigo Nodularis and Depression: A Case Series. Acta Derm Venereol. 2022; 102:adv00754. PMC: 9574697. DOI: 10.2340/actadv.v102.2151. View

12.

Kumar M, Duraisamy K, Chow B . Unlocking the Non-IgE-Mediated Pseudo-Allergic Reaction Puzzle with Mas-Related G-Protein Coupled Receptor Member X2 (MRGPRX2). Cells. 2021; 10(5). PMC: 8146469. DOI: 10.3390/cells10051033. View

13.

Roosterman D, Goerge T, Schneider S, Bunnett N, Steinhoff M . Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. Physiol Rev. 2006; 86(4):1309-79. DOI: 10.1152/physrev.00026.2005. View

14.

Kowalczyk A, Kleniewska P, Kolodziejczyk M, Skibska B, Goraca A . The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp (Warsz). 2014; 63(1):41-52. PMC: 4289534. DOI: 10.1007/s00005-014-0310-1. View

15.

Georgakopoulos J, Croitoru D, Felfeli T, Alhusayen R, Lansang P, Shear N . Long-term dupilumab treatment for chronic refractory generalized prurigo nodularis: A retrospective cohort study. J Am Acad Dermatol. 2021; 85(4):1049-1051. DOI: 10.1016/j.jaad.2021.02.038. View

16.

Stander S, Yosipovitch G, Lacour J, Legat F, Paul C, Reich A . Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol. 2022; 36(10):1820-1825. PMC: 9796585. DOI: 10.1111/jdv.18377. View

17.

Liang Y, Jacobi H, Reimert C, Marcusson J, Johansson O . CGRP-immunoreactive nerves in prurigo nodularis--an exploration of neurogenic inflammation. J Cutan Pathol. 2000; 27(7):359-66. DOI: 10.1034/j.1600-0560.2000.027007359.x. View

18.

Fukushi S, Yamasaki K, Aiba S . Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011; 165(5):990-6. DOI: 10.1111/j.1365-2133.2011.10498.x. View

19.

Chaowattanapanit S, Wongjirattikarn R, Chaisuriya N, Ungarreevittaya P, Poosekeaw P, Winaikosol K . Increased IL-31 expression in serum and tissue protein in prurigo nodularis. Ther Adv Chronic Dis. 2022; 13:20406223221112561. PMC: 9301099. DOI: 10.1177/20406223221112561. View

20.

He Y, Ji S, Yu Q . Effectiveness of baricitinib in prurigo-type atopic dermatitis: A case report. Dermatol Ther. 2021; 34(2):e14878. DOI: 10.1111/dth.14878. View